Norton Rose Fulbright plays a key role in several prominent U.S. antitrust matters, addressing significant issues involving generic pharmaceutical products, algorithmic price-fixing, ‘no-poach’ agreements, and the big tech sector. The group is a trusted advisor to clients involved in class actions, MDL litigation, and criminal antitrust matters in both federal and state courts. In Washington DC, co-chair Robin Adelstein’s extensive antitrust expertise is enhanced by her background in the pharmaceutical sector. Co-chair Neeley Agin rejoined the DC office in March 2024. Based in Houston,
Layne Kruse leads litigation and investigations across the energy, life sciences, insurance, and transportation sectors.